Clinical Trial

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-03-16; most recent amendment 2025-12-22.
Trial Details
NCT Number NCT05295433
Lead Sponsor ModernaTX, Inc.
Conditions Methylmalonic Acidemia
Enrollment 56 participants
Start Date 2022-03-08
Primary Completion 2034-04-02 (estimated)
Study Completion 2034-04-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-23